Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 388

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 388
---
 |   |     | $           | 9,800.00 |   |
| Tranche 1 trigger price |     | $            |  25.00 |   |     | $           |    64.00 |   |
| Tranche 2 trigger price |     | $            |  25.00 |   |     | $           |    77.00 |   |
| Contractual term        |     |              |    3.1 |   |     |             |      4.0 |   |
| Volatility              |     |              |    100 | % |     |             |       90 | % |
| Risk-free interest rate |     |              |   4.23 | % |     |             |     4.20 | % |

F-56

At December 31, 2024 for
the Successor and December 31, 2023 for the Predecessor, the fair value of earnout liability and derivative liabilities were classified
as follows:

The classification of the
fair value of the earnout liability and derivative liabilities and the change in the fair value measurement using significant inputs (Level
3) for the year ended December 31, 2023 and for the period from January 1, 2024 through February 14, 2024 for Predecessor and February
14, 2024 through December 31, 2024 for the Company is presented below:

| Preferred stock warrant liability (Predecessor): |     | Level 1 |   |     | Level 2 |   |     | Level 3 |            |   |     | Total |            |   |
|:-------------------------------------------------|:----|:--------|:--|:----|:--------|:--|:----|:--------|-----------:|:--|:----|:------|-----------:|:--|
| Balance at January 1, 2023                       |     | $       | - |     | $       | - |     | $       |    610,381 |   |     | $     |    610,381 |   |
| Gain on revaluation of warrant liability         |     |         | - |     |         | - |     |         |   (290,264 | ) |     |       |   (290,264 | ) |
| Balance at December 31, 2023                     |     |         |